Prime Medicine proves prime editing in humans, then hands CGD off for bigger markets

A clinical-stage gene-editing biotech building one-time therapies from prime editing, a search-and-replace editor that corrects a mutation without cutting both DNA strands.

That prime editing — a precise search-and-replace gene editor — could correct disease-causing mutations and become a platform for one-time genetic therapies.

Came out of stealth in 2021 with US$315M; Bristol Myers Squibb paid US$110M upfront in 2024 for a CAR-T collaboration with up to US$3.5B in milestones; Prime held US$190M in cash at the end of 2024.

David Liu, who co-invented prime editing at the Broad Institute, co-founded Prime Medicine to turn the technology into therapies; the company emerged from stealth in 2021 with US$315M and set out to correct disease-causing mutations in liver, lung and blood diseases.

Its first clinical program, PM359, edits a patient's own blood stem cells ex vivo to repair the two-base-pair deletion in NCF1 behind p47phox CGD, then returns them after conditioning. On May 19, 2025 the company reported first-patient data: 58% DHR-positive neutrophils by Day 15 and 66% by Day 30 versus a 20% clinical-benefit threshold, with neutrophil engraftment on Day 14 and platelets on Day 19 — roughly twice as fast as the median reported for approved gene-editing therapies — and no PM359-related serious adverse events. The same day it announced it would not independently advance CGD: 25% of staff were laid off, CEO Keith Gottesdiener resigned with CFO Allan Reine taking over, and the stock fell 19% to $1.28. On December 7, 2025 the New England Journal of Medicine published two-patient data: 69% and 83% DHR positivity by Day 30, stable for at least six months, with no new CGD-related complications.

Still running as a public biotech focused on Wilson's Disease, Alpha-1 Antitrypsin Deficiency and its BMS CAR-T collaboration. On June 22, 2026 the FDA granted PM359 Regenerative Medicine Advanced Therapy designation, joining Fast Track, Orphan Drug and Rare Pediatric Disease designations, as the company works toward a Biologics License Application.

CGD is genetically simple and functionally measurable: one well-understood mutation and a direct neutrophil-function readout let a two-patient study produce unambiguous proof.

Prime editing avoids double-strand breaks, and May 2025 data showed engraftment twice as fast as approved gene-editing therapies: neutrophils Day 14 and platelets Day 19 versus Days 27 and 35.

The milestone is hard and dated: NEJM-published results of 69% and 83% DHR-positive neutrophils by Day 30 versus a 20% threshold, durable for six-plus months with no related serious adverse events.

The follow-through was strategic: after clinical proof, Prime pivoted its capital to larger liver targets (Wilson's Disease, AATD) while FDA designations kept PM359 moving toward approval.

A proof market should prove, not pay: CGD validated prime editing in humans, but was too small to sustain the company — Prime Medicine handed it off and targeted bigger diseases.

As of June 2026 Prime Medicine is a public company (Nasdaq: PRME) focused on Wilson's Disease, Alpha-1 Antitrypsin Deficiency and the Bristol Myers Squibb CAR-T collaboration. PM359 holds RMAT, Fast Track, Orphan Drug and Rare Pediatric Disease designations as the company works toward a Biologics License Application, and its first-in-human trial continues follow-up. The open question is whether the platform's clinical proof converts into approved products in larger indications before cash runs out.